Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro
References (43)
- et al.
Stimulation of platelet-derived growth factor-induced DNA synthesis by angiotensin II in rabbit vascular smooth muscle cells
Biochem. Biophys. Res. Commun.
(1990) - et al.
Angiotensin II and noradrenaline increase PDGF-BB receptors and potentiate PDGF-BB stimulated DNA synthesis in vascular smooth muscle
Biochem. Biophys. Res. Commun.
(1990) - et al.
Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro
Exp. Mol. Pathol.
(1981) - et al.
Cytosolic free calcium levels in monolayers of cultured rat aortic smooth muscle cells
J. Biol. Chem.
(1985) - et al.
Dup 532: a second generation of nonpeptide angiotensin II receptor antagonists
Biochem. Biophys. Res. Commun.
(1991) - et al.
A new generation of Ca++ indicators with greatly improved fluorescence properties
J. Biol. Chem.
(1985) - et al.
Characterization of oscillations in cytosolic free Ca2+ concentration and measurement of cytosolic Na+ concentration changes evoked by angiotensin II and vasopressin in individual rat aortic smooth muscle cells
J. Biol. Chem.
(1991) - et al.
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
(1951) - et al.
Comparison of the mitogenic activity of angiotensin II and serotonin on porcine arterial smooth muscle cells
Atherosclerosis
(1991) - et al.
Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulfate and related compounds
Thromb. Res.
(1987)
A recombinant rat vascular AT1 receptor confers growth properties to angiotensin II in chinese hamster ovary cells
Biochem. Biophys. Res. Commun.
Preliminary biochemical characterization of two angiotensin II receptor subtypes
Biochem. Biophys. Res. Commun.
Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, Losartan
Br. J. Pharmacol.
In vitro effect of DuP 753, a nonpeptide angiotensin II receptor antagonist, on human platelets and rat vascular smooth muscle cells
Am. J. Hyper.
Effect of ramipril, an inhibitor of angiotensin converting enzyme, on the response of rat thoracic aorta to injury with a balloon catheter
J. Cardiovasc. Pharmacol.
Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist
J. Pharmacol. Exp. Ther.
Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction
Biochem. Pharmacol.
Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent
J. Pharmacol. Exp. Ther.
Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall
Circ. Res.
Vascular renin-angiotensin: a possible autocrine or paracrine system in control of vascular function
J. Cardiovasc. Pharmacol.
The inhibition of cultured smooth muscle cell growth by saralasin
Cited by (51)
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease
2016, Pharmacology and TherapeuticsCitation Excerpt :With this caveat in mind inhibition of ANG-induced hypertrophy and/or proliferation has been shown in cultured VSMCs from multiple species including rats (Ko et al., 1992; Millet et al., 1992; Sachinidis et al., 1992, 1993; Koh et al., 1994; Sung et al., 1994; Flesch et al., 1995; Itazaki et al., 1995; Kubo et al., 1996; Sachinidis et al., 1996a, 1996b; Graf et al., 1997; Virone-Oddos et al., 1997; Fukuda et al., 1999; Muniz et al., 2001; Touyz et al., 2001b) and humans (Herbert et al., 1994; Mueck et al., 1999; Wang et al., 2012a). Its antagonism has been demonstrated with multiple ARBs including candesartan and its prodrug (Koh et al., 1994; Flesch et al., 1995; Itazaki et al., 1995; Kubo et al., 1996; Sachinidis et al., 1996a, 1996b; Fukuda et al., 1999), eprosartan (Sung et al., 1994), irbesartan (Herbert et al., 1994; Graf et al., 1997; Xi et al., 1999; Muniz et al., 2001; Touyz et al., 2001b), losartan and its active metabolite EXP3174 (Ko et al., 1992; Millet et al., 1992; Sachinidis et al., 1992, 1993; Herbert et al., 1994; Sung et al., 1994; Itazaki et al., 1995; Virone-Oddos et al., 1997), telmisartan (Wang et al., 2012a) and valsartan (Mueck et al., 1999; Wang et al., 2012a). However, a study in isolated rat aorta found that ANG stimulated protein but not DNA synthesis in a losartan-sensitive manner (Holycross et al., 1993), questioning whether the proliferation-enhancing effects observed with cultured VSMC also occur in situ.
Angiotensin II receptor type 1 (AT<inf>1</inf>) selective nonpeptidic antagonists - A perspective
2010, Bioorganic and Medicinal ChemistryCitation Excerpt :Novel imidazole analogs connected to biphenyl moiety through nitrogen (e.g., 32) were reported to show weak potency.98 Bernhart et al. have reported SR 47436 (Irbesartan)99 (33), a potent AT1 selective (IC50 1.3 nM, rat liver) antagonist which antagonized the pressor response to Ang II in a dose-dependent manner (0.1–3 mg/kg, iv and 0.3–30 mg/kg, po).100,101 Compound 33 was found to be 10-fold more potent than losartan (IC50 20.8 nM).
Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
1999, Journal of the American College of Cardiology